Non-myeloablative stem cell transplantation (NST): Chimerism testing as guidance for immune therapeutic manipulations

Leukemia

Volumn 15, Issue 12, 2001, Pages 1967-1975

  Shimoni, A ^a   Nagler, A ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; FLUDARABINE; IDARUBICIN; MELPHALAN; PURINE DERIVATIVE; THYMOCYTE ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER IMMUNOTHERAPY; CHIMERA; CONTROLLED STUDY; CYTOGENETICS; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; FLUORESCENCE ACTIVATED CELL SORTER; FLUORESCENCE IN SITU HYBRIDIZATION; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; LYMPHATIC SYSTEM DISEASE; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RAT; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; STEM CELL TRANSPLANTATION; THYMUS; VARIABLE NUMBER OF TANDEM REPEAT; WHOLE BODY RADIATION;

EID: 0035199030     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402316     Document Type: Review

References (59)

1. Bone marrow transplantation
2. Bone marrow transplantation
3. New strategies for bone marrow transplantation
4. Harnessing graft-versus-malignancy: Nonmyeloablative preparative regimens for allogeneic haematopoietic transplantation. An evolving strategy for adoptive immunotherapy
5. Allogeneic hematopoietic transplantation for acute and chronic myeloid leukemia: Non-myeloablative preparative regimens and induction of the graft-versus-leukemia effect
6. Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation
7. Melphalan and purine analog-containing preparative regimens: Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
8. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic transplantation for acute leukemia
9. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood transplantation: Full donor T-cell chimerism precedes alloimmune responses
10. Mixed hematopoietic chimerism after marrow allografts. Transplantation in the ambulatory care setting
11. The intentional induction of mixed chimerism and achievement of anti-tumor responses following non-myeloablative conditioning therapy and HLA-matched and mismatched donor bone marrow transplantation for malignancies
12. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning
13. Induction of bilateral transplantation tolerance to cellular and perfused allografts and xenografts with donor hematopoietic cells
14. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: The induction of allograft tolerance through mixed lymphohematopoietic chimerism
15. Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis
16. Non-myeloablative conditioning to induce bilateral tolerance after allogeneic bone marrow transplantation in mice
17. Permanent and specific transplantation tolerance induced by a non-myeloablative treatment to a wide variety of allogeneic tissues
18. Prevention and treatment of graft vs host disease by down-regulation of anti-host reactivity with veto cells of host origin
19. Megadose of T cell-depleted bone marrow overcome MHC barriers in sublethally irradiated mice
20. Allogeneic bone marrow transplantation with costimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment
21. Cytokine dysregulation and acute graft-vs-host disease
22. Total body irradiation and acute graft-vs-host disease: The role of gastrointestinal damage and inflammatory cytokines
23. T-cell depleted allogeneic bone marrow transplantation for acute leukemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse
24. Allogeneic cell therapy for relapse leukemia following bone marrow transplantation with donor peripheral blood lymphocytes
25. Metabolism and action of purine nucleo-side analogs
26. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non malignant hematologic diseases
27. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
28. Second allogeneic stem cell transplantation using non-myeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation
29. Transplant lite: Induction of graft vs malignancy using fludarabine based nonablative chemotherapy and allogeneic progenitor-cell transplantation as treatment for lymphoid malignancies
30. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma
31. Allografting with immunosuppressive conditioning of low-dose fludarabine-cyclophosphamide after autografting
32. Allogeneic transplantation for leukemia in patients older than 60 years: Age should not exclude treatment with non-myeloablative regimens
33. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation
34. Hematopoietic cell transplantation in older patients with hematologic malignancies replacing high-dose cytotoxic therapy with graft-versus-tumor effects
35. Mixed lympho haematopoietic chimerism and graft-versus-lymphoma effect after non-myeloablative therapy and HLA mismatched bone-marrow transplantation
36. Nonmyeloablative allogeneic stem cell transplant strategies and the role of mixed chimerism
37. Minimal residual disease post bone-marrow transplantation for hemato-oncological diseases
38. Analysis of the origin of marrow cells in bone marrow transplant recipients using a Y-chromosome-specific in situ hybridization assay
39. Fluorescence in situ hybridization with X and Y chromosome probes for cytogenetic studies on bone marrow transplant cells after opposite sex transplantation
40. Kinetics of chimerism during the early post-transplant period in pediatric patients with malignant and non-malignant hematologic disorders: Implications for timely detection of engraftment, graft failure and rejection
41. Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers
42. Improved single-step PCR assay for sex identification post-allogeneic sex-mismatched BMT
43. Analysis of chimerism within specific leukocyte subsets for detection of residual or recurrent leukemia in pediatric patients after allogeneic stem cell transplantation
44. Chimerism testing after allogeneic stem cell transplantation: Importance of timing and optimal technique for chimerism testing in different clinical-biological situations
45. Chimerism testing after allogeneic stem cell transplantation: Importance of timing and optimal technique for chimerism testing in different clinical-biological situations
46. Studies on hemopoietic chimerism following allogeneic bone marrow transplantation in the molecular biology era
47. Kinetics of engraftment post non-myeloablative stem cell transplantation (full donor chimerism)
48. The effect of donor lymphocyte infusions (DLI) on chimerism and persistent disease after nonmyeloablative hematopoietic stem cell transplant (HSCT)
49. Immunoablative (non-myeloablative) allogeneic SCT results in rapid full donor engraftment and early anti-tumor effects independent of DLI or GVHD prophylaxis withdrawal
50. Degree of early donor T-cell chimerism predicts GVHD and graft rejection in patients with nonmyeloablative hematopoietic stem cell allografts
51. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts
52. Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: A single center experience of 12 children
53. Early immunotherapy on the basis of increasing mixed chimerism - An option to prevent relapse in children with acute leukemias
54. Molecular analysis of chimerism after allogeneic stem cell transplantation for hematologic malignancies as predictive assay for disease recurrence
55. Administration of donor lymphocyte infusions (DLI) leads to superior graft-versus-leukemia-reactions in mixed hematopoietic chimeras than in full donor chimeras
56. A nonmyeloablative regimen for induction of multi-lineage hematopoietic mixed donor-host chimerism in nonmalignant disorders
57. Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia
58. Donor leukocyte infusion for leukemia relapse after allogeneic marrow transplantation: Lack of residual donor hematopoiesis predicts aplasia
59. Feasibility of immunotherapy of relapse leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens